Stay updated on Expanded Access to Upadacitinib Clinical Trial
Sign up to get notified when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.

Latest updates to the Expanded Access to Upadacitinib Clinical Trial page
- ChecktodayChange DetectedExpanded Access page now lists additional eligible conditions for Upadacitinib (e.g., Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Systemic Lupus Erythematosus, Giant Cell Arteritis, Spondyloarthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Rheumatoid Arthritis) and updates related MeSH terms. Older date entries (2026-01-30, 2026-01-29, 2025-04) were removed.SummaryDifference5%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a small platform update to the UI/backend. No study details or user actions are altered by this change.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page shows a new Revision: v3.6.4 label, replacing the previous v3.6.3. This reflects a minor behind-the-scenes update to the site version rather than changes to the study information.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision: v3.6.3 replaces the prior Revision: v3.6.2, reflecting a new site revision. This is a minor update to the page's revision metadata rather than changes to the study details.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, reflecting an underlying system/template update used to render the page.SummaryDifference0.1%

- Check72 days agoChange DetectedThe Intervention/Treatment heading was reformatted from 'Intervention / Treatment' to 'Intervention/Treatment', and the revision tag updated from v3.5.5 to v3.6.0. New navigation entries such as 'Check who can join', 'Find Contact Information', 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study' were added to help users access guidance.SummaryDifference0.7%

Stay in the know with updates to Expanded Access to Upadacitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.